Johnson & Johnson JNJ Innovative Medicine — Selling, marketing and administrative expenses

Other segment segments

Similar metrics at other companies

GEFInnovative Closure Solutions — Selling, general and administrative expenses

$7.4M+42.3%

BDXMedical Essentials — Selling and administrative expense

$185M+12.8%

BDXMedical — Selling and administrative expense

$328M+27.3%

NOVTMedical Solutions — Selling General And Administrative Expense

$16.31M+10.7%

BDXMedical Essentials — Segment Selling and Administrative as a Percent of Revenues

11.2%+0.8pp

BAXMedical Products & Therapies — Selling, general and administrative expenses

$290M+1.4%

Questions, answered.

What is Johnson & Johnson's innovative medicine — selling, marketing and administrative expenses?

Johnson & Johnson (JNJ) reported innovative medicine — selling, marketing and administrative expenses of $2.92B in Q1 2026.

How has Johnson & Johnson's innovative medicine — selling, marketing and administrative expenses changed year-over-year?

Johnson & Johnson's innovative medicine — selling, marketing and administrative expenses increased by 29.1% year-over-year, from $2.26B to $2.92B.

What is the long-term trend for Johnson & Johnson's innovative medicine — selling, marketing and administrative expenses?

Over 3 years (2022 to 2025), Johnson & Johnson's innovative medicine — selling, marketing and administrative expenses has grown at a 5.4% compound annual growth rate (CAGR), from $9.71B to $11.38B.

What does innovative medicine — selling, marketing and administrative expenses mean?

Captures the operating expenses related to the sales force, marketing campaigns, and administrative support for the Innovative Medicine segment. These costs are essential for driving product awareness, physician education, and market access. Monitoring this helps evaluate the efficiency of the segment's commercial infrastructure.